Major Depressive Disorder

Mountain View CA

Description

Phase 3 trial with Relmada Therapeutics at Stanford. This trial will evaluate the therapeutic efficacy of REL-1017 as an adjunctive treatment compared to placebo with antidepressant therapy (ADT) in participants with MDD. Eligible participants who are randomized and complete the 28 days of treatment will be offered the open label extension trial in which all participants will receive active investigational medication for up to 1 year. Basic inclusion criteria include: • Age 18-65 • Diagnosis of Major Depression • Inadequate response to 1-3 courses of an approved antidepressant in the current major depressive episode • BMI between 18 and 30 There is a screening process to determine eligibility. All study related visits and tests are covered by the Sponsor. If interested, please call , or email . July 2022